|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2017)) |
IUPAC Name ![]() |
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
10150 | acalabrutinib |
Synonyms ![]() |
|
ACP-196 | Calquence® | Example 6 [US20140155385 A1] [1] |
Database Links ![]() |
|
CAS Registry No. | 1420477-60-6 (source: INN record) |
GtoPdb PubChem SID | 310264693 |
PubChem CID | 71226662 |
Search Google for chemical match using the InChIKey | WDENQIQQYWYTPO-IBGZPJMESA-N |
Search Google for chemicals with the same backbone | WDENQIQQYWYTPO |
Search PubMed clinical trials | acalabrutinib |
Search PubMed titles | acalabrutinib |
Search PubMed titles/abstracts | acalabrutinib |
Search UniChem for chemical match using the InChIKey | WDENQIQQYWYTPO-IBGZPJMESA-N |
Search UniChem for chemicals with the same backbone | WDENQIQQYWYTPO |
Comments |
Acalabrutinib is an orally available second-generation, selective and irreversible inhibitor of Bruton tyrosine kinase (BTK) [3], being investigated for its potential antineoplastic activity (in multiple haematologic malignancies and solid tumours), as well as a potential therapy for rheumatoid arthritis. Acalabrutinib covalently bonds to Cysteine-481 in BTK. |